EVOTEC STARTS PHASE I CLINIC TRIAL WITH EVT 101
Evotec has announced the initiation of a Phase I study with EVT 101, its NR2B subtype selective NMDA receptor antagonist for the potential treatment of Alzheimer's disease, neuropathic pain and Parkinson's disease.
The study is a double-blind, placebo-controlled Phase I study evaluating the safety, tolerability and pharmacokinetics of EVT 101 in young and elderly healthy volunteers.
EVT 101 is a highly potent and selective antagonist of NR2B subunit containing NMDA receptors. In preclinical studies, the compound shows strong efficacy combined with an improved side-effect profile compared to non-selective NMDA receptor antagonists and has good oral bioavailability and in vivo pharmacokinetics.